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Background: Lymphatic filariasis (LF) is a vector-borne parasitic disease that is being targeted for elimination
through mass drug administration (MDA). The co-distribution of Loa loa in Central Africa poses a significant barrier
to the expansion of the MDA due to risk of severe adverse events (SAEs) associated with the drug ivermectin that is
routinely used. National LF programmes are yet to significantly scale up in co-endemic areas and need a practical
approach to make preliminary decisions based on the mapping status and potential treatment strategies.
Methods: We reviewed relevant data available to WHO and in the literature for LF-L. loa endemic countries to
develop a simple method to support the scale-up of MDA to eliminate LF.
Results: A basic model for national LF programmes to work from at the administrative or implementation unit (IU) level
has been developed for LF – L. loa co-endemic countries. The model includes five practical steps, which comprise the
development of a national filarial database and a simple classification system to help determine the mapping status and
most appropriate treatment strategy. Steps are colour-coded and linked to a general decision tree, which is also presented.
Conclusions: This IU-level model is simple to follow and will help LF elimination programmes develop an action plan and
scale up the implementation of alternative treatment strategies in L. loa co-endemic areas. The model could be further
developed to incorporate the additional complexity of IUs where an intervention is required to eliminate onchocerciasis,
particularly in hypo-endemic areas where ivermectin has not been used.Background
Lymphatic filariasis (LF) is a disabling parasitic disease
transmitted by mosquitoes, and is endemic across tropical
regions of the world. LF is currently being targeted for
elimination coordinated through the Global Programme to
Eliminate LF (GPELF), which is driven by two main goals
including i) interrupting transmission with mass drug
administration (MDA) of albendazole in combination with
ivermectin or diethylcarbamazine citrate (DEC), and ii)
morbidity management and disability prevention (MMDP)
for those affected by clinical conditions [1]. The GPELF has* Correspondence: kingj@who.int
4Department of Control of Neglected Tropical Diseases, World Health
Organization, Geneva, Switzerland
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zemade significant progress with 62 of 73 countries having
implemented MDA, and 18 of these 62 countries no longer
requiring MDA [2]. However, there have been challenges in
starting and scaling up MDA in a number of sub-Saharan
African countries due to the co-distribution of the filarial in-
fection caused by Loa loa (also known as loiasis, tropical eye
worm), and the potential risk of severe adverse events (SAEs)
associated with the ingestion of ivermectin in individuals
with high L. Loa microfilarial (Mf) loads [3–6]. Therefore, in
LF and L. loa co-endemic areas alternative treatment strat-
egies that exclude the use of ivermectin are required to ensure
safe treatment, adequate coverage and operational impact.
In 2012 the World Health Organization (WHO) developed
a provisional strategy for interrupting LF transmission in lo-
iasis endemic countries [7], which also took into account thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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(CDTI) being implemented by the African Programme for
Onchocerciasis Control (APOC), targeting areas with greater
than 20% nodule prevalence [8, 9]. The LF strategy recom-
mends that where L. loa infection is present and onchocer-
ciasis (oncho) is non-endemic or hypo-endemic (defined as
less than 20% of nodule prevalence), MDA should be imple-
mented with biannual albendazole in combination with vec-
tor control. In LF endemic areas where oncho endemicity is
defined as meso- or hyper-endemic, the strategy can also be
used if CDTi has not been implemented [10]. The addition
of vector control is considered important given that similar
Anophelesmosquitoes transmit LF and malaria, and the mal-
aria control programmes currently scaling up insecticide-
treated mosquito net distribution in particular, could help to
accelerate the reduction in LF transmission [11–13]. The
efficacy of this alternative strategy has been demonstrated in
ongoing operational research from Republic of Congo [14].
There is now a priority to move forward and roll out the
most appropriate treatment strategies for LF elimination in
L. loa endemic countries, taking the filarial co-endemicity,
oncho - CDTi history and mapping status into account.
The first and most fundamental step is to develop a basic
framework or model for national LF programmes to work
from and make decisions at the administrative or imple-
mentation level based on all available data.
Methods
We reviewed all of the following data available to WHO
and in the literature for LF – L. loa endemic countries:
1) Subnational endemicity status of LF and L. loa
2) Progress of MDA or CDTi
3) Reported use of bed nets
4) Subnational population estimates
We identified key indicators required to inform the
elimination strategy decisions. Then developed a simple
method to support national programmes review available
data on these indicators and make suggestions of how to
obtain missing data necessary to plan appropriate MDA
strategy recommended by WHO for LF elimination.
This paper presents a five step practical model/approach
to be used in LF – L. loa co-endemic countries, and
includes the development of a national filarial database and
a simple classification system to help determine the
mapping status and most appropriate treatment strategy. A
general decision tree is also presented.
Results
Scope
There are 10 LF endemic countries in West and Central
Africa that are co-endemic with L. Loa which may require al-
ternative treatment strategies to interrupt transmission.These countries are diverse in terms of L. Loa prevalence as
determined by the rapid assessment procedure for loiasis
(RAPLOA), as well as population size at risk [6, 15], and
include Angola (est. pop 7.9 mil at risk), Cameroon (est. pop
8.3 mil at risk), Central Africa Republic (CAR; est. pop 2.8
mil at risk), Chad (est. pop 0.3 mil at risk), Congo (est. pop
1.4 mil at risk), Democratic Republic of Congo (DRC; est.
pop 43.9 mil at risk), Equatorial Guinea (est. pop 0.42 mil at
risk), Gabon (est. pop 0.2 mil at risk), Nigeria (est. pop 79.4
mil at risk), and South Sudan (est. pop 9.8 mil at risk).
The administrative unit which a country uses as the basis
for implementing MDA is defined as the implementation
unit (IU), and is usually the district or equivalent for LF
elimination programmes [16]. Based on IU endemicity status
available at the end of 2014, there were an estimated 1911
IUs across the ten countries, where the alternative strategy
could be implemented. In order for national LF Programmes
to determine which IUs require albendazole MDA and
where additional assessments might be necessary across their
country, the following five practical steps are recommended.
Step 1: build a filarial-information database
First, it is essential to develop a database with information
on filarial endemicity and CDTi status for each IU in the
country. The filarial data are related to the three main filarial
diseases - LF, loiasis and oncho. Five countries have not ini-
tiated MDA for LF, but have implemented CDTi for oncho.
The MDA status data are related to the standard implemen-
tation of ivermectin for oncho, namely CDTi, and if it has
ever been initiated or completed for either LF or oncho.
Data on the endemicity and MDA status need to be collated
from both historical and current national mapping data,
Ministry reports, APOC/WHO sources, and the scientific
literature, and entered into a simple spreadsheet or data file.
Step 2: classify the endemicity and mapping status
Second, a simple classification of the filarial endemicity is
needed to determine whether any mapping needs to be con-
ducted and what treatment strategies are recommended. For
each IU, the data on LF, L. loa and oncho endemicity are
classified and coded simply as non-endemic (No= 0), en-
demic (Yes = 1) or unknown (4 =Unknown). Examples of
these coded data and how they help to determine the map-
ping status and treatment strategies are shown in Fig. 1a-d.
Where endemicity is unknown, new surveys may be
needed. The combination of the LF and L. loa endemicity
codes are used to define four mapping status categories as
outlined in Fig. 1b. The first category includes i) ‘Mapped’ =
if LF has been mapped and LF is endemic (code = 1) or
non-endemic (code = 0), indicating that mapped endemic
areas need to proceed and consider the most appropriate
treatment strategies. Non-endemic areas require no treat-
ment. The following three categories are related to un-
mapped areas and include ii) ‘Not Mapped, L. loa Absent ‘if
ab
c
d
Fig. 1 Tabulated filarial endemicity, MDA status, mapping status and treatment strategies. (a) Endemicity and MDA status (b) Endemicity and
mapping status (c) Treatment strategy for mapped areas (d) Example of endemicity and MDA coded combinations
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endemic (code = 0), iii) ‘Not Mapped, L. loa Present’= if LF
is unknown (code = 4) and L. loa is endemic (code = 1), and
iv) ‘Not Mapped, L. loa Unknown’ if the LF and L. loa
endemicity indicators were both unknown (code = 4).Step 3: determine the status of current/ongoing treatment
strategies
Third, the status of MDA with ivermectin or CDTi for each
IU must be determined. MDA has been initiated (code = 1)
or not (code = 0) across the entire IU, or partially in selected
areas. Communication with sub-national levels may berequired to understand whether any preventive chemother-
apy is ongoing in the IU. Because oncho transmission zones
are not consistent with LF administrative/implementation
units, CDTi may be implemented only in a part of an IU, i.e.
villages in selected riverine areas instead of the entire IU.
Therefore, the extent of CDTi within the IU should be noted
i.e. IU/district-wide (No = 0, Yes = 1), or Partial IU areas
(Partial = 2) or Unknown (Unknown= 4).Step 4: define the required treatment strategy
Fourth, to determine the treatment strategy of an IU, the
combination of the endemicity, mapping and MDA status
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The first two categories include i) ‘No MDA required’= if LF
is mapped and endemicity is non-endemic (code = 0), and ii)
‘MDA required but risk unknown’ if LF is endemic (code = 1),
and L. loa is unknown (code = 4), indicating that L. Loa map-
ping may be required if L. loa could be endemic (reported
cases, documented vector, or vector habitat). However, the
alternative strategy of biannual albendazole in combination
with vector control may start while the L. loa mapping is be-
ing conducted and the associated risk assessment completed.
The next two categories relate to standard MDA, and
include iii) ‘Standard MDA 1’= if LF endemicity is endemic
(code = 1), and L. loa endemicity is non-endemic (code = 0)
and iv) ‘Standard MDA 2’ if LF, L. loa and oncho are
endemic (code = 1) and CDTi has been initiated in the IU
(code = 1) in all sub-areas. Here, it is important to establish
links with the national oncho programme to assess theFig. 2 Decision tree to determine the mapping and/or treatment strategytreatment duration, and therapeutic and geographical cover-
age rates as low or limited coverage, and/or areas where
CDTi is just starting, may have pockets for potential SAEs.
Other factors such as the transience of communities, migra-
tion patterns and population turnover (i.e. birth/deaths
rates) should also be considered.
The final categories relate to alternative treatments, and
include v) ‘Alternative strategy 1’ if LF, L. loa and oncho
are endemic (code = 1) and CDTi has not been initiated
(code = 0) or has not been implemented in all sub-areas of
the IU (code = 2), and vi) ‘Alternative Strategy 2’ if LF and
L. loa are endemic (code = 1), and oncho is non-endemic
(code = 0) or unknown (code = 4), and CDTi has not been
initiated (code = 0). Here, is it important to establish links
with the national malaria programme and assess vector
control type, duration and geographical coverage as this
may help to facilitate the scale up of these strategies.process
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Based on the above information, a simple decision tree
can be developed for each country to inform the steps at
IU–level as shown in Fig. 2. This decision tool supple-
ments the filarial database and can be adapted to na-
tional programmatic policy.
For ‘Mapping Status’, the methodology will depend on the
L. loa co-endemicity, and if ‘absent’ then standard LF map-
ping may be conducted, whereas if ‘present’ then additional
assay/new diagnostic tools may be needed. If the L. loa status
is ‘unknown’ and suspected to be present, then integrated
mapping may be appropriate at different spatial scales using
a combination of tools (e.g. BinaxNOW Filariasis immuno-
chromatographic test (ICT) or Alere Filariasis Test Strip
(FTS) Alere, Scarborough, ME, United States) [17], Mf and
RAPLOA. For ‘Treatment Strategy’, the approach will depend
on L. loa and oncho endemicity and CDTi status. IUs requir-
ing more information before determining the strategy will be
highlighted through this process. Links with oncho elimination
and malaria programmes need to be developed to ascertain
MDA status and vector control duration and coverage rates.
These data and categories can further be colour-coded to
develop maps and help to highlight the geographical pat-
terns of the mapping status of each IU, the most appropriate
treatment strategies and where potential alternative map-
ping approaches can be considered. Figure 3a and b present
examples of mapping status and treatment strategy maps
within an area of a country, and highlight how the IUs may
need different resources to confirm the LF endemicity and
treatment within an IU.
Discussion
These five practical steps are fundamental for LF – L. loa
co-endemic country programmes to plan and scale up theFig. 3 Example of maps highlighting mapping and treatment requirements in LFimplementation of biannual albendazole MDA. This initial
model/approach is focussed on developing a national filarial
database, reviewing the co-endemicity, mapping needs and
treatment requirements at IU-level as a starting point. In
principle, the scaling up of this readily available and safe al-
ternative MDA strategy is possible without further detailed
assessment of LF and L. loa. The required medicines are do-
nated and available through WHO for requesting countries
[18]. With the additional necessary commitment and re-
sources for distribution, monitoring and evaluation, coun-
tries can get on track towards meeting the elimination
target. However, it will be important to be aware of potential
challenges related to the logistics of mobilising populations
for twice yearly treatment and ensuring high bed net cover-
age. It is recommended that LF – L. loa co-endemic country
programmes document and share the challenges as they
arise, so that all programmes can benefit and learn from
each other’s experience.
The recent reports of an association of high-density L.
loa microfilaremia with ‘false’ positive ICT indicate a
potential for overestimating LF endemicity [19, 20]. Further
investigation of such an association is warranted. Any add-
itional mapping, monitoring or transmission assessment
surveys (TAS) for LF in loiasis endemic areas should in-
clude the collection of additional blood specimens for other
filarial diagnostic assays [21]. New mapping approaches
and tools might be required in known L. loa co-endemic
areas. The new diagnostic Cell Scope Loa devise provides a
tool with the capacity to quickly and affordably assess the
L. loa positivity of individual patients, potentially allowing
for ivermectin-based treatment to occur in a selective man-
ner in LF - L. loa co-endemic areas and could be of critical
importance in high risk SAE locations requiring alternative
strategies [22, 23]. Further, in areas where LF and L. loa– Loa co-endemic area. (a) Unmapped LF areas (b) Mapped treatment areas
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mapping’ method using a combination of FTS, MF
for both LF and L. loa, and RAPLOA may help deter-
mine the extent and/or ecological pattern of co-
endemicity, and provide further insights into the best
diagnostic tools to use. A combination of micro- inte-
grated- filarial mapping has previously been used to
determine high L. Loa prevalence areas where iver-
mectin should not be used [24, 25]. The advantages
and disadvantages of each mapping strategy should be
carefully considered.
For this first step, we did not incorporate oncho elimin-
ation strategies. However, the same approach could be
used for identifying the action required to define treat-
ment strategies and help to develop a practical and safe
action plan for oncho elimination. The Cell Scope Loa
devise is probably more critical to use in oncho-L. loa
endemic areas as there is currently no effective alternative
strategy. Micro-integrated-filarial mapping may also be
considered in the decision to expand ivermectin use in
CDTi naive areas for elimination of oncho, especially in
‘hypo-endemic hotspots’ where oncho transmission is
low, and the risk of L. Loa and SAEs is high [9, 26]. In
addition to new mapping and diagnostic approaches, it is
essential that LF Programmes now collaborate closely
with the oncho and malaria programmes to collect and
compile data on oncho CDTi and vector control thera-
peutic and geographical coverage rates for each IU. New
links with soil transmitted helminths (STH) programmes
will also be important as they scale up biannual albenda-
zole MDA and potentially move into co-endemic areas
[27]. Compiling this type of cross-programmatic data,
and developing interlinking intervention databases and
maps will be necessary to assess the geographical overlap,
and determine if these different interventions have
been - are - or will be - sufficient to provide impact and
elimination potential for LF in a complex, dynamic
environment [28].
Conclusion
This paper presents a five step practical model/
approach to be used in LF – L. loa co-endemic coun-
tries, and includes the development of a national filar-
ial database and a simple classification system to help
determine the mapping status and most appropriate
treatment strategy. LF data templates for the ten coun-
tries have already been developed based on reported
endemicity data or in literature to facilitate discussion
and planning. This will help LF elimination pro-
grammes develop an action plan and start to scale up
the implementation of treatment strategies. Further,
the model could be further developed to incorporate
the additional complexity of oncho, particularly in
hypo-endemic areas.Abbreviations
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